2011 looks set to be a bumper year for generics, with patents from some of the biggest selling drugs set to expire.
2011’s biggest patent expiries
Home/Policies & Legislation | Posted 22/04/2011 0 Post your comment
Just looking at the top five selling drugs, US sales of more than US$10 billion will be open to competition by the generics industry.
Key patent expiries, according to data from EvaluatePharma, include Lipitor (atorvastatin – Pfizer), Zyprexa (olanzapine – Eli Lilly), Levaquin (levofloxacin – Johnson & Johnson), Concerta (methylphenidate – Johnson & Johnson) and Protonix (pantoprazole – Pfizer). These patent expiries, while being very good news for the generics industry and patients could deal a major blow to some of the largest pharmaceutical companies.
In 2010, with US$10.8 billion in worldwide sales, Lipitor accounted for 15.8% of Pfizer’s total revenue. While in 2010, Zyprexa’s worldwide revenues were just over US$5 billion, or nearly 22% of Eli Lilly’s full year sales.
Once drugs lose patent protection, lower-price generics rapidly gain market share, often siphoning off as much as 90% of sales. Benefits to patients are substantial, with generics averaging about 30% of the price of the brand-name originals.
Related article
2012’s biggest patent expiries
Source: EvaluatePharma
Guidelines
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
WHO’s revised guideline to safe and effective biosimilar products
Reports
First approvals of similar biotherapeutics in seven Latin American countries
Biosimilar terminology: insights from seven Latin American countries
Comments (0)
Post your comment